December 27, 2023 -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer ...
December 13, 2023– Luye Pharma Group today announced that two of its in-house developed innovative formulations have been included on the National Reimbursement Drug List for Basic Medical Insur...
December 13, 2023 -- Luye Diagnostics Group today announced that Great Basin Toxigenic C. difficile Direct Test (CDF2), independently developed by Vela Operations USA, has been approved by U.S. Food a...
Lurbinectedin is a new chemical compound with a novel mechanism of action. It’s been the only new chemical entity approved by the U.S. FDA for the treatment of relapsed SCLC over the past 26 yea...
The 6th China International Import Expo (CIIE) kicked off on November 5th, 2023. With its spillover effect, the CIIE provides a major platform for the internationalization of Traditional Chinese Medic...
Shanghai, October 31, 2023 -- Luye Pharma Group today announced that its exclusive new drug, Rivastigmine Twice Weekly Transdermal Patch, has been approved by China's National Medical Products Adm...
Shanghai, October 9, 2023 - Luye Pharma Group today announced the submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) through the 505(b)(2) pathway for its LY03...
Luye Pharma Ltd, a subsidiary of Luye Pharma Group has launched an innovative new product for the treatment of Alzheimer's disease.Zeyzelf® twice weekly rivastigmine transdermal patch is for the s...
On September 7, 2023, Luye Life Sciences Group, in collaboration with the Ministry of Higher Education, Science, and Innovation of Uzbekistan, celebrated a signing ceremony in Tashkent for their joint...
Remarkable payoff for innovationStrong revenue growthAccelerated commercialization worldwideLuye Pharma Group (2186.HK) announced its 2023 half year results and recent developments on August 29, 2023....
TOP